According to recently reported clinical data, ACE2 inhibitors and angiotensin receptor blockers (ARBs), the leading SARS-CoV-2 treatments, have not improved clinical outcomes in adult patients with severe COVID-19 and may even worsen them39. Here, ACE2 is linked to COVID-19.